Rationale and design of the Helping Ease Renal failure with Bupi Yishen compared with the Angiotensin II Antagonist Losartan (HERBAAL) trial: A randomized controlled trial in non-diabetes stage 4 chronic kidney disease

BMC Complementary and Alternative Medicine

Volumn 15, Issue 1, 2015, Pages

  Mao, Wei ^a   Zhang, Lei ^a   Zou, Chuan ^a   Li, Chuang ^a   Wu, Yifan ^a   Su, Guobin ^a   Guo, Xinfeng ^a   Wu, Yuchi ^a   Lu, Fuhua ^a   Lin, Qizhan ^a   Wang, Lixin ^a   Bao, Kun ^a   Xu, Peng ^a   Zhao, Daixin ^a   Peng, Yu ^a   Liang, Hui ^a   Lu, Zhaoyu ^a   Gao, Yanxiang ^a   Jie, Xina ^a   Zhang, La ^a   Wen, Zehuai ^a,b   Liu, Xusheng ^a   more..

^a GUANGDONG PROVINCIAL HOSPITAL OF CHINESE MEDICINE   (China)

^b GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BUPI YISHEN; CHINESE DRUG; LOSARTAN; PLACEBO; UNCLASSIFIED DRUG; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; HERBACEOUS AGENT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR FUNCTION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; LIVER FUNCTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STUDY DESIGN; TREATMENT OUTCOME; KIDNEY; PATHOPHYSIOLOGY; RENAL INSUFFICIENCY;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; DRUGS, CHINESE HERBAL; HUMANS; KIDNEY; LOSARTAN; RENAL INSUFFICIENCY;

EID: 84941010172     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/s12906-015-0830-1     Document Type: Article

References (38)

1. W C, H W, XQ D. Epidemiologic study of chronic kidney disease in Guangzhou urban area. Chin J Nephrol. 2007;17(298):2038-47.
2. Zhang L, Zuo L, Xu G, Wang F, Wang M, Wang S, et al. Community-based screening for chronic kidney disease among populations older than 40 years in Beijing. Nephrol Dial Transplant. 2007;22(4):1093-9.
3. Astor BC, Hallan SI, Miller ER, Yeung E, Coresh J. Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. Am J Epidemiol. 2008;167(10):1226-34.
4. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038-47.
5. Abboud H, Henrich WL. Clinical practice. Stage IV chronic kidney disease. N Engl J Med. 2010;362(1):56-65.
6. Snyder S, Pendergraph B. Detection and evaluation of chronic kidney disease. Am Fam Physician. 2005;72(9):1723-32.
7. Bethesda M. National Institute of Diabetes and Digestive and Kidney Disease. In: USRDS: United State Renal Data System Annual Data Report. USA: The National Institute of Health; 2009. http://www.usrds.org/atlas09.aspx .
8. Hou FF, Xie D, Zhang X, Chen PY, Zhang WR, Liang M, et al. Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. J Am Soc Nephrol. 2007;18(6):1889-98.
9. Turgut F, Balogun RA, Abdel-Rahman EM. Renin-angiotensin-aldosterone system blockade effects on the kidney in the elderly: benefits and limitations. Clin J Am Soc Nephrol. 2010;5(7):1330-9.
10. Wang YJ, He LQ, Sun W, Lu Y, Wang XQ, Zhang PQ, et al. Optimized project of traditional Chinese medicine in treating chronic kidney disease stage 3: a multicenter double-blinded randomized controlled trial. J Ethnopharmacol. 2012;139(3):757-64.
11. Dong F, Cheng J, Lin S, Hu Z, Chen G, He L. The clinical research on serum cystatin-C alteration on stage II chronic kidney disease with gubenquduyishen decoction treatment. J Ethnopharmacol. 2010;131(3):581-4.
12. Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med. 2006;354(2):131-40.
13. Dou C, Wan Y, Sun W, Zhagn H, Chen J, Shui G, et al. Mechanism of Chinese herbal medicine delaying progression of chronic kidney disease. Zhongguo Zhong Yao Za Zhi. 2009;34(8):939-43.
14. Zuo C, Xie XS, Qiu HY, Deng Y, Zhu D, Fan JM. Astragalus mongholicus ameliorates renal fibrosis by modulating HGF and TGF-beta in rats with unilateral ureteral obstruction. J Zhejiang Univ Sci B. 2009;10(5):380-90.
15. Pu GJ, Wang C, Zheng PD, He LQ. Effects of No.2 Renal Failure Recipe on expressions of cyclooxygenase-2 and -1 mRNAs in rats with chronic renal failure. Zhong Xi Yi Jie He Xue Bao. 2009;7(11):1067-72.
16. Peng A, Gu Y, Lin SY. Herbal treatment for renal diseases. Ann Acad Med Singapore. 2005;34(1):44-51.
17. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39:S1-S266.
18. Guideline for TCM Internal Medicine Diagnosis and Treatment of Common Diseases. In.: Association Of Chinese Medicine; 2008.
19. Zheng S. Guideline for Chinese Medicine Innovation. Beijing: Chinese Medicine Science and Technology press; 2002.
20. Douglas JG, Agodoa L. ACE inhibition is effective and renoprotective in hypertensive nephrosclerosis: the African American Study of Kidney Disease and Hypertension (AASK) trial. Kidney Int Suppl. 2003;83:S74-6.
21. Levey AS, Greene T, Sarnak MJ, Wang X, Beck GJ, Kusek JW, et al. Effect of dietary protein restriction on the progression of kidney disease: long-term follow-up of the Modification of Diet in Renal Disease (MDRD) Study. Am J Kidney Dis. 2006;48(6):879-88.
22. Kramer BK, Schweda F. Ramipril in non-diabetic renal failure (REIN study), Ramipril Efficiency in Nephropathy study. Lancet. 1997;350(9079):736. 736-737.
23. Inker LA, Shaffi K, Levey AS. Estimating glomerular filtration rate using the chronic kidney disease-epidemiology collaboration creatinine equation: better risk predictions. Circ Heart Fail. 2012;5(3):303-6.
24. Loke YK PDHA. Adverse effects/Higgins JPT, Greens. Cochrane Handbook for Systematic Review of Intervention., Version 5.0.1 edn: The Cochrane Collaboration; 2008.
25. The use of the WHO-UMC system for standardised case causality assessment. The Uppsala Monitoring Centre. http://www.who.int/medicines/areas/quality_safety/safety_efficacy/WHOcausality_assessment.pdf
26. User verification of performances for precision and trueness; approved guideline. In: Clinical and Laboratory Standard Institute (CLSI) Document EP15-A2. Edited by Wayne, 2nd edition edn. PA: CLSI; 2005: 64.
27. Yao CM, Yang XW. Bioactivity-guided isolation of polyacetylenes with inhibitory activity against NO production in LPS-activated RAW264.7 macrophages from the rhizomes of Atractylodes macrocephala. J Ethnopharmacol. 2014;151(2):791-9.
28. Li M, Wang W, Xue J, Gu Y, Lin S. Meta-analysis of the clinical value of Astragalus membranaceus in diabetic nephropathy. J Ethnopharmacol. 2011;133(2):412-9.
29. Sun YX. Immunological adjuvant effect of a water-soluble polysaccharide, CPP, from the roots of Codonopsis pilosula on the immune responses to ovalbumin in mice. Chem Biodivers. 2009;6(6):890-6.
30. Yongxu S, Jicheng L. Structural characterization of a water-soluble polysaccharide from the roots of Codonopsis pilosula and its immunity activity. Int J Biol Macromol. 2008;43(3):279-82.
31. Lee YG, Kim JY, Lee JY, Byeon SE, Hong EK, Lee J, et al. Regulatory effects of Codonopsis lanceolata on macrophage-mediated immune responses. J Ethnopharmacol. 2007;112(1):180-8.
32. Jin H, Sakaida I, Tsuchiya M, Okita K. Herbal medicine Rhei rhizome prevents liver fibrosis in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. Life Sci. 2005;76(24):2805-16.
33. Gao J, Wang F, Wang W, Su Z, Guo C, Cao S. Emodin suppresses hyperglycemia-induced proliferation and fibronectin expression in mesangial cells via inhibiting cFLIP. Plos One. 2014;9(4):e93588.
34. Chen Q, Pang L, Huang S, Lei W, Huang D. Effects of emodin and irbesartan on ventricular fibrosis in Goldblatt hypertensive rats. Pharmazie. 2014;69(5):374-8.
35. Liao JC, Chang WT, Lee MS, Chiu YJ, Chao WK, Lin YC, et al. Antinociceptive and anti-inflammatory activities of Cuscuta chinensis seeds in mice. Am J Chin Med. 2014;42(1):223-42.
36. Zhou GJ, Wang W, Xie XM, Qin MJ, Kuai BK, Zhou TS. Post-harvest induced production of salvianolic acids and significant promotion of antioxidant properties in roots of Salvia miltiorrhiza (Danshen). Molecules. 2014;19(6):7207-22.
37. Tao L, Li X, Zhang L, Tian J, Li X, Sun X, et al. Protective effect of tetrahydroxystilbene glucoside on 6-OHDA-induced apoptosis in PC12 cells through the ROS-NO pathway. Plos One. 2011;6(10):e26055.
38. Ng TB, Liu F, Wang HX. The antioxidant effects of aqueous and organic extracts of Panax quinquefolium, Panax notoginseng, Codonopsis pilosula, Pseudostellaria heterophylla and Glehnia littoralis. J Ethnopharmacol. 2004;93(2-3):285-8.